Efficacy of adrenocorticotropic hormone in children with frequently relapsing or steroid-dependent nephrotic syndrome.
10.3760/cma.j.cn112140-20210901-00725
- Author:
Yi XIE
1
;
Jing Jing WANG
1
;
Hai Dong FU
1
;
Ai Min LIU
1
;
Jian Hua MAO
1
Author Information
1. Department of Nephrology, the Children's Hospital, Zhejiang University School of Medicine,National Clinical Research Center for Child Health, Hangzhou 310052, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adrenocorticotropic Hormone/therapeutic use*;
Child;
Child, Preschool;
Female;
Glucocorticoids/therapeutic use*;
Humans;
Immunosuppressive Agents/therapeutic use*;
Male;
Nephrotic Syndrome/drug therapy*;
Recurrence;
Retrospective Studies;
Steroids;
Treatment Outcome
- From:
Chinese Journal of Pediatrics
2022;60(4):334-338
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the efficacy and safety of adrenocorticotropic hormone (ACTH) in children with frequently relapsing or steroid-dependent nephrotic syndrome. Methods: The clinical data of 38 children with frequently relapsing or steroid-dependent nephrotic syndrome who were admitted to the Department of Nephrology, the Children Hospital, Zhejiang University School of Medicine from January 2015 to December 2020 were retrospectively analyzed. The general information, clinical manifestations, laboratory data of the children and follow-up (till 12 months after treatment) were collected. The patients were divided into ACTH group and Glucocorticoid (GC) group according to treatment plan. Cumulative remission, average recurrence rate, GC dosage, height and weight change and peripheral blood CD19+B lymphocyte count were compared between the two groups to evaluate the efficacy and adverse reactions of ACTH. Fisher's exact test, t test or rank sum test was used for comparison between groups. Results: Among the 38 patients, 28 were male and 10 were female, aged 84 (24, 180) months; 19 were in ACTH group and 19 were in GC group. The cumulative remission rate of 12 months in ACTH group was higher than that in GC group (9/19 vs. 2/19,χ²=6.81,P=0.009), the average recurrence rate was lower than that in GC group ((0.7±0.8) vs. (1.7±1.1) times, t=-3.27, P=0.011), and the average dosage of GC was lower than that in GC group ((0.27±0.16) vs. (0.51±0.27) mg/(kg·d), t=-3.21, P=0.014). The increase in height was higher than that in the GC group (4 (3,5) vs. 3 (2, 3) cm/year, Z=2.58, P=0.010), and the peripheral blood CD19+B lymphocyte count was lower than that in the GC group ((223±149)×106 vs. (410±213)×106/L,t=-3.35, P=0.009). In safety, 19 cases had transient decreased urine volume, 7 cases had hyperglycemia, and 3 cases had hypertension during the infusion of ACTH, which could be relieved after drug withdrawal. Conclusion: ACTH has a better effect on children with frequently relapsing or steroid-dependent nephrotic syndrome, which can improve cumulative sustained remission rate, lower relapses rate and decrease the dosage of GC, with good safety.
